TrialNature communications2024

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.

Harshabad Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.